Use our chat feature to speak with one of our expert consultants who can help you identify if medical cannabis can help you.
2 min read
Lucy MacKinnon
As the UK's only all-in-one medical cannabis subscription service, we are enthused to be working alongside over 100 other stakeholders within the CIC to advance the medical cannabis industry and empower patients.
With members representing each link in the entire cannabis supply chain, the CIC unites charities, clinical groups, and research bodies to revolutionise the industry.
Offering participation in working groups, representation within the government, training courses, as well as events attendance and networking, The Cannabis Industry Council acts as a collective voice to campaign for change.
Commenting on the collaboration, our CEO and Founder Mason Soiza said:
"We are thrilled to be joining The Cannabis Industry Council. By uniting with like-minded organisations, we can collectively drive positive change in the medical cannabis landscape.
Our vision aligns with the CIC's mission to enhance responsible access to cannabis, improve patient outcomes, and contribute to the industry's health, environmental, and economic benefits."
Mike Morgan-Giles, The Cannabis Industry Council's CEO, mirrored this excitement commenting:
"We are delighted to welcome Releaf to the Cannabis Industry Council. Their decision to join highlights how the CIC is becoming increasingly recognised across the sector.
"The medical cannabis sector faces a range of regulatory and policy challenges, and we look forward to Releaf contributing to developing solutions in the interests of the sector."
Here at Releaf, we are passionate about removing the stigma that surrounds medical cannabis in the UK and are dedicated to maintaining a seamless service for our patients by providing their prescribed medications with clarity and compassion.
Our innovative approach allows patients to utilise our comprehensive online platform to simplify the process, offering a convenient and secure way to acquire, consume, and benefit from medicinal cannabis. Accessing medical cannabis can be challenging due to the stigma surrounding it. However, Releaf makes it simple with our tailored monthly packages, specialist consultations for medical cannabis, and a unique medical cannabis card for protection, all based on a patients cannabis prescription.
It is important to seek medical advice before starting any new treatments. The patient advisors at Releaf are available to provide expert advice and support. Alternatively, click here to book a consultation with one of our specialist doctors.
Get comprehensive care, convenience, and confidence with an all-in-one treatment plan.
Am I eligible?With five years of journalism and healthcare content creation under her belt, Lucy strives to improve medical cannabis awareness and access in the UK by producing high quality, credible content.
Our articles are written by experts and reviewed by medical professionals or compliance specialists. Adhering to stringent sourcing guidelines, we reference peer-reviewed studies and scholarly research. View our editorial policy.
Need more help?
In today's write-up, we will explain all the factors that can and do affect the price of medical cannabis cultivars. Here at Releaf, we want to ensure that our patients are well-informed about their medication options, including the pricing factors.
Sam North
In the last two decades, global plastic production has doubled, with 400 million tonnes of plastic waste now produced every year. As one of the only UK clinics to provide medical cannabis flower in eco-friendly packaging, Releaf is committed to finding more sustainable solutions this Plastic Free July and is taking steps towards a plastic-free future.
Sarah Sinclair
Medical cannabis was legalised in the UK in 2018 for patients with health conditions known to respond to cannabis-based treatments, if conventional or licensed medications have failed to meet their needs. Because one of these health conditions is Multiple Sclerosis, Releaf are joining MS-UK for a free Webinar on the 21st of August, to explain how these treatments can be safely incorporated into MS treatment plans.
Lucy MacKinnon
